Payment overview · 2025
General Payments
$1,789.36
17 reported records · 16 companies
Healthcare provider profile · identity verified
Mimoza Zaka, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · ROCHESTER HILLS, MI · NPI 1053786954
Verified facts
What the public records show
CMS Open Payments records show Mimoza Zaka, NP received $1,789.36 in general payments during 2025 across 17 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 14.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUDORZA PRESSAIR as an associated drug or biological on 89 records involving 63 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tudorza Pressair by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INVEGA SUSTENNA as an associated drug or biological on 39068 records involving 11966 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Invega Sustenna by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xarelto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $258.30 | 14.4% | 2 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $144.96 | 8.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$131.90 | 7.4% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.99 | 7.0% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $124.74 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $124.74 | 7.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $124.74 | 7.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $121.83 | 6.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $107.10 | 6.0% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $106.96 | 6.0% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $102.15 | 5.7% | 1 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $94.74 | 5.3% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $93.70 | 5.2% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $49.02 | 2.7% | 1 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $44.42 | 2.5% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $35.07 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,789.36 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $144.96 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $132.30 | 1 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $131.90 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $126.00 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| EPIDIOLEX Normalized: epidiolex |
Drug | JAZZ PHARMACEUTICALS INC. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $121.83 | 1 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $107.10 | 1 | 2025 |
Source payment records
|
|||||
| SPRAVATO Normalized: spravato |
Drug | Janssen Pharmaceuticals, Inc | $106.96 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $102.15 | 1 | 2025 |
Source payment records
|
|||||
| DRIZALMA SPRINKLE Normalized: drizalma sprinkle |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $94.74 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $93.70 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $49.02 | 1 | 2025 |
Source payment records
|
|||||
| Titan Normalized: titan |
Device | COLOPLAST CORP | $44.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $35.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TUDORZA PRESSAIR open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 63 recipient NPIs · example record 1206133584 |
Tudorza Pressair · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | INVEGA SUSTENNA open payments reported associated product |
CMS Open Payments — General Payments 39068 supporting records · 11966 recipient NPIs · example record 1174223262 |
Invega Sustenna · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 341 | 70 |
| Amlodipine Besylate | Amlodipine Besylate | 275 | 45 |
| Losartan Potassium | Losartan Potassium | 156 | 30 |
| Lisinopril | Lisinopril | 150 | 29 |
| Latanoprost | Latanoprost | 142 | 25 |
| Metoprolol Succinate | Metoprolol Succinate | 140 | 27 |
| Furosemide | Furosemide | 118 | 37 |
| Levothyroxine Sodium | Levothyroxine Sodium | 114 | 22 |
| Eliquis | Apixaban | 96 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 86 | 13 |
| Omeprazole | Omeprazole | 82 | 22 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 82 | 19 |
| Potassium Chloride | Potassium Chloride | 79 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 75 | 15 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 16 |
| Gabapentin | Gabapentin | 66 | 23 |
| Carvedilol | Carvedilol | 64 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 64 | 13 |
| Metformin Hcl | Metformin Hcl | 63 | 11 |
| Pantoprazole Sodium | Pantoprazole Sodium | 62 | 18 |
| Alendronate Sodium | Alendronate Sodium | 59 | suppressed |
| Jardiance | Empagliflozin | 59 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 57 | 12 |
| Famotidine | Famotidine | 52 | 15 |
| Trulicity | Dulaglutide | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 51 | 14 |
| Donepezil Hcl | Donepezil Hcl | 49 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 44 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Mirtazapine | Mirtazapine | 41 | 12 |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 38 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 36 | suppressed |
| Olanzapine | Olanzapine | 35 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 35 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Bumetanide | Bumetanide | 32 | suppressed |
| Allopurinol | Allopurinol | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 18 |
| Rhopressa | Netarsudil Mesylate | 24 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 20 | suppressed |
| Prednisone | Prednisone | 20 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 19 | suppressed |
| Cephalexin | Cephalexin | 19 | 18 |
| Finasteride | Finasteride | 19 | suppressed |
| Metformin Er Osmotic | Metformin Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Nystatin | Nystatin | 18 | 14 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Ozempic | Semaglutide | 16 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 16 | suppressed |
| Simvastatin | Simvastatin | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 14 | suppressed |
| Haloperidol | Haloperidol | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Ritalin | Methylphenidate Hcl | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Timolol Maleate | Timolol Maleate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Gemtesa | Vibegron | 12 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 12 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Tudorza Pressair | Aclidinium Bromide | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,789.36 · 17 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, Auvelity, BENLYSTA, DRIZALMA SPRINKLE, Dexcom G6 Transmitter, EPIDIOLEX, INGREZZA, Leqembi, PYRUKYND, QUTENZA, REXULTI, SPRAVATO, SYMPLICITY G3, Titan, UZEDY, WAINUA, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error